FindTrial
Sign In

Research on Evaluation Method of Homologous Recombination Deficient Status in Ovarian Cancer Based on Next Generation Sequencing

Evaluation Method of Homologous Recombination Deficient Status Based on Next Generation Sequencing in Predicting the Efficacy of Drug Response in Ovarian Cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035621
Enrollment
Unknown
Registered
2020-08-15
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Gold Standard:clinical outcomes
Index test:homologous&#32
recombination&#32
deficient&#32
status&#32
score&#32
based&#32
on&#32
NGS.

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Pathologically diagnosed as ovarian cancer; 3. Have been treated with platinum or PARPi and have a clear clinical response record; 4. Have performed BRCA testing or HRR-related gene testing; 5. With available tumor tissues and storage time is no more than 5 years, enough to cut 20 5 µm pieces to ensure sufficient DNA content.

Exclusion criteria

Exclusion criteria: 1. The total sample content or remaining content does not meet the testing requirements; 2. Lack of important clinical information (such as lack of efficacy of platinum treatment or PARPi).

Design outcomes

Primary

MeasureTime frame
ORR of platinum chemotherapy;—

Countries

China

Contacts

Public ContactQianlan Yao

Fudan University Shanghai Cancer Center

yaoqianlan@foxmail.com+86 18121299587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026